Prostate Cancer Therapeutics Market Insights
Prostate cancer is caused by the uncontrolled growth of the cells in the prostate gland. Prostate cancer is the most common cancer in men in the U.S., after skin cancer. According to the American Community Survey, 2016, in U.S. prostate cancer is the second leading cause of death among the cancer deaths in men. Almost all prostate cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Other types of prostate cancer are rare; these include: Sarcomas, small cell carcinomas, neuroendocrine tumors and transitional cell carcinomas. Advanced stage of prostate cancer can cause men to urinate more often or have a weaker flow of urine, but these symptoms can also be caused by benign prostate conditions. In 2017, the American Cancer Society estimated around 161,360 new diagnoses of prostate cancer in the U.S., leading to around 26,730 fatalities. As the cause of the cancer is not known, there is no definite way to prevent prostate cancer. The American Cancer Society (ACS) and the National Comprehensive Cancer Network (NCCN) recommends that all men over age 40 should have an annual rectal examination and that men have an annual prostate-specific antigen (PSA) test beginning at age of 50 years.
Rising implications associated with prostate cancer are expected to affect the prostate cancer therapeutics market
Prostate cancer incidence is strongly related to age, with the highest incidence rates being in older men. According to National Cancer Registry Ireland, 2011, median age at prostate cancer diagnosis in Ireland was 67 years with 38.9% of cases being diagnosed in men and 21.3% in men 75+ years. Median age at death was 80 with 70.3% of deaths occurring in men 75+ years. Moreover, Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection are also the factors which expected to boost the prostate cancer therapeutics market. However, high cost associated with drugs, and poor reimbursement of treatment cost may affect the prostate cancer therapeutics negatively.
The global prostate cancer therapeutics market was valued at US$ 8,191.11 million in 2016 and is expected to witness a CAGR of 7.5% during the forecast period (2017 – 2025).
Table 1. Prostate Cancer Drugs in Pipeline
|Indocyanine Green (ICG)
|Leuprolide Acetate, Prednisone, Docetaxel and Apalutamide
Source: Clinical Trials.gov
Endeavor to introduce highly effective therapies for prostate cancer would support the market growth
Many research organizations and universities are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, some pipeline products which are in phase 2 studies, such as Avelumab (Duke University Medical Center), Metformin (Mansoura University), LY2452473 (Dana-Farber Cancer Institute) are expected to arrive in the market in the near future. Furthermore, many products that are about to face patent expiry during the forecast period will also contribute in the growth of the generic prostate cancer therapeutics market. Many pharmaceutical companies are also focusing on introducing their respective drugs in different countries to boost the sales of their products. For instance, in December, 2016, Sanofi’s prostate cancer drug name Jevtana (cabazitaxel) for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) was approved by Scottish Medicines Consortium (SMC) for restricted use within NHS Scotland, due to which Scotland has now collaborated with health authorities in Northern Ireland, England and Wales. Thereby, reducing potential disparities in care across the UK for this vulnerable group of patients.
Key players operating in the prostate cancer therapeutics market include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.